We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Moderna, a frontrunner in the race to develop a COVID-19 vaccine, announced Thursday that its phase 3 study for the candidate could start by early summer. Read More
A failed study of nearly 1,400 COVID-19 patients taking hydroxychloroquine is the latest to cast doubt on the drug’s benefit as a coronavirus treatment. Read More
How the federal government is handling the distribution of Gilead’s remdesivir for treatment of COVID-19 patients is sparking outrage and sharp criticism from physicians’ groups and doctors across the nation. Read More
Famotidine, a heartburn medicine better known as Pepcid, has been added to the FDA’s drug shortage list shortly after it became known that the drug is being tested as a COVID-19 treatment. Read More
Incyte and Novartis are planning a second phase 3 clinical trial in the U.S. of their JAK inhibitor Jakafi (ruxolitinib) as a COVID-19 treatment. Read More
The FDA’s Center for Biologics Evaluation and Research (CBER) Director Peter Marks said Wednesday that he hopes the center can help expedite vaccine development to lead to a COVID-19 vaccine in nine months. Read More